Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Review reveals nonsteroidal anti-inflammatory drugs are effective for acute pain and 5 treatments are effective for chronic pain.

Workouts at gyms to combat muscle loss caused by GLP-1 drugs are gaining traction, but do they differ from regular strength ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

The demand for glucagon-like peptide 1 (GLP-1s) receptor agonists for overweight/obesity has created a clinical conundrum for ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management.

Only around one in every 10 treatments were found to be effective in relieving lower back pain, according to a new study ...

Mounjaro, Eli Lilly's diabetes and obesity drug, is now available in India at a fraction of its US price. It offers treatment for weight loss and diabetes control, but watch out for the side effects ...